The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
O’Brien, C. A., Pollett, A., Gallinger, S., & Dick, J. E. (2007) · Nature · doi:10.1038/nature05372 · Cited by 4,087
Identification and expansion of human colon-cancer-initiating cells
Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., & De Maria, R. (2007) · Nature · doi:10.1038/nature05384 · Cited by 3,998
Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M., Bruns, C. J., & Heeschen, C. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.06.002 · Cited by 2,897
Identification and expansion of the tumorigenic lung cancer stem cell population
Eramo, A., Lotti, F., Sette, G., Pilozzi, E., Biffoni, M., Di Virgilio, A., Conticello, C., Ruco, L., Peschle, C., & De Maria, R. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402283 · Cited by 1,707
Frequent EpCam protein expression in human carcinomas
Went, P. T. H., Lugli, A., Meier, S., Bundi, M., Mirlacher, M., Sauter, G., & Dirnhofer, S. (2004) · Human Pathology · doi:10.1016/j.humpath.2003.08.026 · Cited by 819
Nuclear signalling by tumour-associated antigen EpCAM
Maetzel, D., Denzel, S., Mack, B., Canis, M., Went, P., Benk, M., Kieu, C., Papior, P., Baeuerle, P. A., Munz, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1824 · Cited by 719
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies.
Herlyn, M., Steplewski, Z., Herlyn, D., & Koprowski, H. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.3.1438 · Cited by 656
Epithelial Cell Adhesion Molecule
Trzpis, M., McLaughlin, P. M. J., de Leij, L. M. F. H., & Harmsen, M. C. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070152 · Cited by 578
The biology of the 17–1A antigen (Ep-CAM)
Balzar, M., Winter, M. J., de Boer, C. J., & Litvinov, S. V. (1999) · Journal of Molecular Medicine · doi:10.1007/s001099900038 · Cited by 545
EpCAM (CD326) finding its role in cancer
Baeuerle, P. A., & Gires, O. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603494 · Cited by 527
Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule.
Litvinov, S. V., Velders, M. P., Bakker, H. A., Fleuren, G. J., & Warnaar, S. O. (1994) · The Journal of cell biology · doi:10.1083/jcb.125.2.437 · Cited by 524
Riethmüller, G., Holz, E., Schlimok, G., Schmiegel, W., Raab, R., Höffken, K., Gruber, R., Funke, I., Pichlmaier, H., Hirche, H., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1788 · Cited by 517
Hybrid antibodies can target sites for attack by T cells
Staerz, U. D., Kanagawa, O., & Bevan, M. J. (1985) · Nature · doi:10.1038/314628a0 · Cited by 492
Fishelson, Z. (2003) · Molecular Immunology · doi:10.1016/s0161-5890(03)00112-3 · Cited by 400
Went, P., Vasei, M., Bubendorf, L., Terracciano, L., Tornillo, L., Riede, U., Kononen, J., Simon, R., Sauter, G., & Baeuerle, P. A. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602924 · Cited by 387
Pattern and prognostic factors in patients with malignant ascites: a retrospective study
Ayantunde, A. A., & Parsons, S. L. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl499 · Cited by 385
The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation
Münz, M., Kieu, C., Mack, B., Schmitt, B., Zeidler, R., & Gires, O. (2004) · Oncogene · doi:10.1038/sj.onc.1207610 · Cited by 368
Malignant ascites: Systematic review and guideline for treatment
Becker, G., Galandi, D., & Blum, H. E. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.018 · Cited by 349
Hoffmann, P., Hofmeister, R., Brischwein, K., Brandl, C., Crommer, S., Bargou, R., Itin, C., Prang, N., & Baeuerle, P. A. (2005) · International Journal of Cancer · doi:10.1002/ijc.20908 · Cited by 344
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336
Nagy, J. A., Masse, E., Herzberg, K. T., Meyers, M., Yeo, K. T., Yeo, T.-K., Sioussat, T. M., & Dvorak, H. F. (1995) · PubMed · Cited by 281
Burges, A., Wimberger, P., Kümper, C., Gorbounova, V., Sommer, H., Schmalfeldt, B., Pfisterer, J., Lichinitser, M., Makhson, A., Moiseyenko, V., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2769 · Cited by 257
Self-citationHigh Ep-CAM Expression is Associated with Poor Prognosis in Node-positive Breast Cancer
Spizzo, G., Gastl, G., Obrist, P., Went, P., Dirnhofer, S., Bischoff, S., Mirlacher, M., Sauter, G., Simon, R., Stopatschinskaya, S., et al. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000036787.59816.01 · Cited by 254
Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice
Parulekar, W. R., & Eisenhauer, E. A. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh182 · Cited by 223
Lindhofer, H., Mocikat, R., Steipe, B., & Thierfelder, S. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.1.219 · Cited by 213
Self-citationPunt, C. J., Nagy, A., Douillard, J.-Y., Figer, A., Skovsgaard, T., Monson, J., Barone, C., Fountzilas, G., Riess, H., Moylan, E., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09836-7 · Cited by 213
Malignant ascites: past, present, and future
Adam, R. A., & Adam, Y. G. (2004) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2004.01.035 · Cited by 209
Zeidler, R., Reisbach, G., Wollenberg, B., Lang, S., Chaubal, S., Schmitt, B., & Lindhofer, H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1246 · Cited by 204
Self-citationSpizzo, G., Went, P., Dirnhofer, S., Obrist, P., Moch, H., Baeuerle, P. A., Mueller-Holzner, E., Marth, C., Gastl, G., & Zeimet, A. G. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.03.035 · Cited by 201
Zeidler, R., Mysliwietz, J., Csánady, M., Walz, A., Ziegler, I., Schmitt, B., Wollenberg, B., & Lindhofer, H. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1237 · Cited by 189
Self-citationBalzar, M., Briaire-de Bruijn, I. H., Rees-Bakker, H. A. M., Prins, F. A., Helfrich, W., de Leij, L., Riethmüller, G., Alberti, S., Warnaar, S. O., Fleuren, G. J., et al. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.7.2570-2580.2001 · Cited by 181
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
Ruf, P., & Lindhofer, H. (2001) · Blood · doi:10.1182/blood.v98.8.2526 · Cited by 174
Self-citationThe Current and Future Management of Malignant Ascites
Smith, E. M., & Jayson, G. C. (2003) · Clinical Oncology · doi:10.1053/clon.2002.0135 · Cited by 167
Nagy, J. A., Morgan, E. S., Herzberg, K. T., Manseau, E. J., Dvořàk, A. M., & Dvorak, H. F. (1995) · PubMed · Cited by 163
Peritoneal inflammation – A microenvironment for Epithelial Ovarian Cancer (EOC)
Freedman, R. S., Deavers, M. T., Liu, J., & Wang, E. (2004) · Journal of Translational Medicine · doi:10.1186/1479-5876-2-23 · Cited by 144
Donin, N., Jurianz, K., Ziporen, L., Schultz, S., Kirschfink, M., & Fishelson, Z. (2003) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2003.02066.x · Cited by 139
A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects
Strome, S. E., Sausville, E. A., & Mann, D. L. (2007) · The Oncologist · doi:10.1634/theoncologist.12-9-1084 · Cited by 134
Malignant ascites: a 2-year review from a teaching hospital
Parsons, S. L., Lang, M. W., & Steele, R. J. (1996) · European Journal of Surgical Oncology · doi:10.1016/s0748-7983(96)80009-6 · Cited by 117
Ruf, P., Gires, O., Jäger, M., Fellinger, K., Atz, J., & Lindhofer, H. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603881 · Cited by 102
Self-citationDetection of cancer cells in effusions from patients diagnosed with gynaecological malignancies
Davidson, B., Risberg, B. Å., Kristensen, G. B., Kvalheim, G., Emilsen, E., Bjåmer, A., & Berner, A. (1999) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280050393 · Cited by 100
Stoecklein, N. H., Siegmund, A., Scheunemann, P., Luebke, A. M., Erbersdobler, A., Verde, P. E., Eisenberger, C. F., Peiper, M., Rehders, A., Esch, J. S. A., et al. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-165 · Cited by 99
Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies (αEpCAM × αCD3)
Riesenberg, R., Büchner, A., Pohla, H., & Lindhofer, H. (2001) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540104900711 · Cited by 96
Self-citationNormal Human Immune Peritoneal Cells: Subpopulations and Functional Characteristics
Kubicka, U., Olszewski, W. L., Tarnowski, W., Bielecki, K., Ziolkowska, A., & Wierzbicki, Z. (1996) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.1996.d01-297.x · Cited by 90
Amann, M., Brischwein, K., Lutterbuese, P., Parr, L., Petersen, L., Lorenczewski, G., Krinner, E., Bruckmeier, S., Lippold, S., Kischel, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2182 · Cited by 90
Fields, A. L. A., Keller, A. M., Schwartzberg, L. S., Bernard, S. A., Kardinal, C. G., Cohen, A., Schulz, J., Eisenberg, P. D., Forster, J. K., & Wissel, P. S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5710 · Cited by 83
Malignant ascites: demographics, therapeutic efficacy and predictors of survival.
Mackey, J. R., & Venner, P. M. (1996) · PubMed · Cited by 67
Marmé, A., Strauß, G., Bastert, G., Grischke, E., & Moldenhauer, G. (2002) · International Journal of Cancer · doi:10.1002/ijc.10562 · Cited by 58
Schmitt, M. W., Schmitt, A., Reinhardt, P., Thess, B., Manfras, B. J., Lindhofer, H., Riechelmann, H., Wiesneth, M., & Gronau, S. (2004) · PubMed · Cited by 57
Self-citationGeneral aspects of cytokine-release syndrome: timing and incidence of symptoms.
Jeyarajah, D. R., & Thistlethwaite, J. R. (1993) · PubMed · Cited by 56
Diaz‐Arias, A. A., Loy, T. S., Bickel, J. T., & Chapman, R. K. (1993) · Diagnostic Cytopathology · doi:10.1002/dc.2840090509 · Cited by 56
Ströhlein, M. A., Siegel, R., Jäger, M., Lindhofer, H., Jauch, K., & Heiss, M. M. (2009) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-28-18 · Cited by 52
Self-citationHuman antiglobulin response to foreign antibodies: therapeutic benefit?
DeNardo, G. L., Bradt, B. M., Mirick, G. R., et al. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-002-0350-y · Cited by 51
Test System for Trifunctional Antibodies in 3D MCTS Culture
Hirschhaeuser, F., Leidig, T., Rodday, B., Lindemann, C., & Mueller‐Klieser, W. (2009) · SLAS DISCOVERY · doi:10.1177/1087057109341766 · Cited by 47
Azinovic, I., DeNardo, G. L., Lamborn, K. R., Mirick, G. R., Goldstein, D. S., Bradt, B. M., & DeNardo, S. J. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0148-4 · Cited by 45
Morecki, S., Lindhofer, H., Yacovlev, E., Gelfand, Y., Ruf, P., & Slavin, S. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.03.005 · Cited by 38
Self-citationBispecific Antibodies for Cancer Therapy
Hollander, N. (2009) · Immunotherapy · doi:10.2217/1750743x.1.2.211 · Cited by 38
Riechelmann, H., Wiesneth, M., Schauwecker, P., Reinhardt, P., Gronau, S., Schmitt, A., Schroen, C., Atz, J., & Schmitt, M. W. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0283-6 · Cited by 30
The Pathogenesis of Malignant Ascites
Tamsma, J. T. (2007) · Springer eBooks · doi:10.1007/978-0-387-48993-3_6 · Cited by 27
Molema, G., Tervaert, J. W. C., Kroesen, B. J., Helfrich, W., Meijer, D. K. F., & de Leij, L. F. M. H. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0945 · Cited by 25
Parsons, S., Murawa, P., Koralewski, P., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3000 · Cited by 21
Belau, A. K., Pfisterer, J., Wimberger, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.5556 · Cited by 16
Krueger, C. M., Berdov, B. A., Roman, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.15529 · Cited by 12
Lindhofer, H., Schoberth, A., Pelster, D., Hess, J., Herold, J., & Jäger, M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3014 · Cited by 12
Self-citationAntitumour effects of a bispecific trivalent antibody in multicellular tumour spheroids.
Walz, A., Mack, B., Schmitt, B., Gires, O., Wollenberg, B., & Zeidler, R. (2004) · PubMed · Cited by 10
Bokemeyer, C., Heiss, M., Gamperl, H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3036 · Cited by 10
Self-citationParsons, S. L., Hennig, M., Linke, R., Klein, A., Lahr, A., Lindhofer, H., & Heiss, M. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.e14000 · Cited by 9
Self-citationStröhlein, M. A., Lordick, F., Rüttinger, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3033 · Cited by 6
Jäger, M., Schoberth, A., Theissen, B., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3029 · Cited by 4
Ströhlein, M. A., Schemanski, O. C., Jäger, M., et al. (2008) · Cited by 4
Heiss, M. M., Linke, R., Friccius-Quecke, H., et al. (2009) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(09)71229-7 · Cited by 3
Cited by
Control of Metastasis by NK Cells
López-Soto, A., Gonzalez, S., Smyth, M. J., & Galluzzi, L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.009 · Cited by 736
Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572
“Catumaxumab, for example, contains an EpCAM-specific “half ” antibody connected via disulfide bonds in the hinge region to a CD3-specific “half-mAb” (49).”
BackgroundThe present and future of bispecific antibodies for cancer therapy
Klein, C., Brinkmann, U., Reichert, J. M., & Kontermann, R. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00896-6 · Cited by 490
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
Dual targeting strategies with bispecific antibodies
Kontermann, R. (2012) · mAbs · doi:10.4161/mabs.4.2.19000 · Cited by 435
Metadata
- Authors
- Seimetz, D., Lindhofer, H., & Bokemeyer, C.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2010-10
- Volume
- 36
- Issue
- 6
- Pages
- 458-467
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2008184262
- Cited by
- 284
- References
- 72
- FWCI
- 19.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.